Localization of salmon cardiac peptide (sCP) in the heart of salmon (Salmo salar L.)

Exploring cardiac plasticity in teleost: the role of humoral modulation

The fish heart represents an established natural model for evaluating basic mechanisms of the coordinated physiological reactions which maintain cardiac steady-state. This is due to its relatively simple design, but also to its multilevel morpho-functional flexibility which allows adequate responses to a variety of intrinsic (body size and shape, swimming performance, etc.), and extrinsic (temperature, salinity, oxygen level, water chemistry, etc.) factors related to the animal life style. Nowadays, although many gaps are still present, a huge literature is available about the mechanisms that fine-tune fish cardiac performance, particularly in relation to the influence exerted by substances possessing cardio-modulatory properties. Based on these premises, this review will provide an overview of the existing current knowledge regarding the humoral control of cardiac performance in fish. The role of both classic (i.e. catecholamines, angiotensin II and natriuretic peptides), and emerging cardioactive substances (i.e. the chromogranin-A-derived peptides vasostatins, catestatin and serpinin) will be illustrated and discussed. Moreover, an example of cardiomodulation elicited by peptides (e.g., nesfatin-1) associated to the regulation of feeding and metabolism will be provided. The picture will hopefully emphasize the complex circuits that sustain fish cardiac performance, also highliting the power of the teleost heart as an experimental model to deciphering mechanisms that could be difficult to explore in more elaborated cardiac morpho-functional designs.

Distribution and co-localization of diversified natriuretic peptides in the eel heart

Atrial and B-type natriuretic peptides (ANP and BNP) are cardiac hormones important for cardiovascular and body fluid regulation. In some teleost species, an additional member of the natriuretic peptide family, ventricular NP (VNP), has been identified. In this study, we examine tissue distribution of these three NPs in the eel heart. Quantitative real-time PCR showed that anp is almost exclusively expressed in atria, bnp equally in atria and ventricles and vnp three-fold more in ventricles than in atria. The amount of bnp transcript overall in the heart was 1/10 those of anp and vnp. There was no difference in transcript levels between freshwater and seawater-acclimated fishes. Immunohistochemistry using specific antisera and in situ hybridization using gene-specific probes showed that NP signals were detected in most atrial and ventricular myocytes with some regional differences in density. Because of high sequence similarity of the three NPs, each of the three NP antisera individually was pre-incubated with 10^-8 M of the other two non-targeted cardiac NPs to increase the specificity. A few atrial myocytes contained all three NPs in the same cell. Immuno-electron microscopy identified many dense-core vesicles containing ANP in atria and VNP in ventricles and some vesicles contained both ANP and VNP as demonstrated using pre-absorbed antisera. Based on these data and those of previous studies, we suggest that in eels ANP is secreted from atria in a regulatory pathway and VNP from ventricles in a constitutive pathway. In addition, VNP, not BNP, is the principal ventricular hormone in eels.

Hypoxia increases the release of salmon cardiac peptide (sCP) from the heart of rainbow trout (Oncorhynchus mykiss) under constant mechanical load in vitro

Our aim was to study the effects of hypoxia on the release of salmon cardiac peptide (sCP) from an isolated heart ventricle of trout during a constant mechanical load. Trout heart ventricles were studied in vitro. The ventricle was placed in an organ bath at 12 °C in which a constant mechanical load could be imposed on the ventricle while buffer solution was circulating. Ventricles were field-stimulated with a supramaximal voltage pulse at a rate of about 0.3 s⁻¹. Samples of 1 ml were collected at an interval of 10 min for 200 min from the organ bath and assessed with a radioimmunoassay for sCP. After a control period of 20 min, ventricles were exposed to hypoxia produced with N₂ gassing (n = 9) or to hypoxia with 20 mM BDM, a nonselective myosin ATPase inhibitor locking cross-bridges in a pre-power-stroke state inhibiting force production with normal electrical activity (n = 10). In this model and setup, hypoxia stimulated the release of sCP, but the interindividual variation in the response was large. At the end of hypoxia exposure, the concentration of sCP in the organ bath was about sixfold higher than at the start of the exposure (P < 0.05, one-way ANOVA for repeated measurements, followed by Dunnett's multiple comparison test). When BDM was introduced into the bath, the ventricle still secreted sCP but the hypoxic response was smaller than in the experiments without BDM. In the trout heart ventricle, there is a hypoxia-sensitive component in the release mechanism of sCP which is independent of contraction.

Physiology of natriuretic peptides: The volume overload hypothesis revisited

The discovery of the natriuretic peptide system in the early 1980s aroused great interest among clinical cardiologists. The heart was not a mechanical pump alone, but also an endocrine organ that had powerful effects on blood circulation. Natriuretic peptides caused both natriuresis and diuresis, and they responded to a volume overload which caused either stretch or pressure on the heart. As a result, the findings led to the conclusion that the human body had a hormone with effects similar to those of a drug which treats high blood pressure. Later, it became evident that the volume contraction was fortified by extrarenal plasma shift. Here, a hypothesis is presented in which the role of natriuretic peptides is to regulate oxygen transport as the volume contraction leads to hemoconcentration with an increased oxygen-carrying capacity. Wall stress, either chemical or mechanical, changes the oxygen gradient of the myocardium and affects the diffusion of oxygen within a myocyte. In support of this hypothesis, hypoxia-response elements have been found in both the atrial natriuretic peptide and the brain natriuretic peptide genes.

Localization of natriuretic peptides in the cardiac pacemaker of Atlantic salmon (Salmo salar L.)

This study describes the location of the primary pacemaker at the sino-atrial (SA) junction and the localization of salmon cardiac peptide (sCP) and ventricular natriuretic peptide (VNP) in Atlantic salmon (Salmo salar L.). The pacemaker tissue appeared lightly stained and composed of: (1) wavy nerve bundles with oval elongated wavy appearing nuclei with pointed ends, (2) ganglion cells (12-22 μm) with granular cytoplasm and (3) wide muscle fibers with large nuclei (modified cardiomyocytes) clearly distinguishing them from the other myocardial cells. Pacemaker tissue was further evaluated using immunohistochemical staining. Immunoreactivity of natriuretic peptides (sCP and VNP) antisera showed specific staining in pacemaker ganglion cells in addition to the cardiomyocytes. Positive staining with anti-CD3ɛ antisera in the pacemaker ganglion cells is a novel finding in teleosts and is consistent with observations in mammals. In conclusion, the Atlantic salmon pacemaker was shown to be located at the SA node and to harbor sCP and VNP peptides, suggesting a possible neuromodulatory and/or neurotransmitter role for these cardiac hormones within the teleost heart.

Hyperthermia induced atrial natriuretic peptide expression and deviant heart development in Atlantic salmon Salmo salar embryos

Heart abnormalities are increasingly recognized as a problem in salmon aquaculture. Fish in early life-stages are particularly susceptible to teratogens, including elevated water temperature. Recently, heat-induced mRNA expression of the cardiac hormone atrial natriuretic peptide (ANP), which is known to be involved in modulation of cardiac growth and regulation of cardiac homeostasis, was demonstrated in Atlantic salmon (Salmo salar) embryos by RAP-PCR. The relation between heat sensitive ANP expression and heart abnormalities was explored in two experiments. In an experiment with short-term exposure, salmon eggs were heat shocked at 16 degrees C at eight different embryonic stages from gastrulation till completion of somitogenesis. The RT-PCR results showed that the ANP mRNA expression was down-regulated at the onset of heart formation at the gastrula stage, while the transcription became heat inducible from the fusioning of the heart tube around the 15th-20th somite stage and onwards. This was confirmed by whole-mount in situ hybridization, which also showed that ANP is exclusively expressed in the heart of Atlantic salmon embryos. In a second long-term experiment, salmon embryos were incubated at either 10 degrees C (high temperature) or 8 degrees C (controls) from fertilization till first feeding, and subsequently reared within normal conditions to an average size of 52 g. The long-term hyperthermic embryos showed up-regulated ANP transcription at the approximately 9th and approximately 20th somite stage and at the completion of somitogenesis. The cardiosomatic index [CSI; (ventricle weight/body weight) *100] demonstrated a significant decrease in the relative heart weight of fish incubated at 10 degrees C during the embryogenesis compared with controls. In these fish, aplasia of septum transversum was observed in 2 of 25 fish, resulting in abnormally shaped hearts situated partly within the abdominal cavity. Altogether, our results demonstrate that hyperthermia both induce deviant development of heart and associated structures and up-regulation of ANP transcription during embryogenesis. A possible role of ANP in development of heart malformations is thus suggested.